Prostate cancer: Androgen deprivation therapy and bone loss.
Amir
Eitan
E
Tannock
Ian F
IF
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001862:Bone Resorption / Q000209:etiology* / Q000517:prevention & control*; D000069448:Denosumab; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000628:therapy*; D053245:RANK Ligand / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D007987:Gonadotropin-Releasing Hormone; D000069448:Denosumab